Which peptides are studied for bone and growth conditions?

Short answer

8 profiles here are grouped under “Bone and growth”: 7 FDA-approved and 1 not FDA-approved.

Each entry below quotes its profile and links to the full answer there.

FDA-approved 7

Not FDA-approved 1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    TYMLOS (abaloparatide) injection, solution · SPL version 19 · published 2026-08-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  2. 2
    Drugs@FDA application NDA208743 · original submission status AP · 2017-04-28 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    MIACALCIN (calcitonin salmon) injection, solution · SPL version 9 · published 2026-06-19 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA: MIACALCIN (calcitonin salmon), NDA 017808 · original approval July 3, 1986 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  5. 5
    PARSABIV (etelcalcetide) injection, solution · SPL version 15 · published 2026-03-16 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  6. 6
    Drugs@FDA: PARSABIV (etelcalcetide), NDA 208325 · original approval February 7, 2017 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  7. 7
    Drugs@FDA: INCRELEX (mecasermin [rDNA origin]), application 021839 · original approval August 30, 2005 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  8. 8
    INCRELEX (mecasermin) injection · SPL version 4 · published 2025-11-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  9. 9
    YORVIPATH (palopegteriparatide) injection, solution · SPL version 10 · published 2026-11-09 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  10. 10
    Drugs@FDA: YORVIPATH (palopegteriparatide), NDA 216490 · original approval August 9, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  11. 11
    Teriparatide injection, solution · SPL version 10 · published 2026-09-21 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  12. 12
    Drugs@FDA application NDA021318 · original submission status AP · 2002-11-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  13. 13
    Drugs@FDA application NDA211939 · original submission status AP · 2019-10-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  14. 14
    Drugs@FDA application ANDA211097 · original submission status AP · 2023-11-16 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  15. 15
    Drugs@FDA application NDA218771 · original submission status AP · 2024-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  16. 16
    Drugs@FDA application ANDA214412 · original submission status AP · 2026-10-23 · dataset 2026-11-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked November 15, 2026

  17. 17
    VOXZOGO (vosoritide) kit · SPL version 16 · published 2025-11-26 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  18. 18
    Drugs@FDA application NDA214938 · original submission status AP · 2021-11-19 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  19. 19
    FDA briefing document for MOTS-c ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  20. 20
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  21. 21
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026